Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 388 participants.
Also called NCT02054897
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 388 participants
- Sponsor
- Registry
-
NCT02054897 -
2013-000632-94
-
- Other papers using this trial's data
- Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial
- Semaglutide as a therapeutic option for elderly patients with type 2 diabetes: Pooled analysis of the SUSTAIN 1-5 trials
- Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, Italy, Japan, Mexico, Romania, Russia, South Africa, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02054897. Randomized; double masking; primary purpose treatment. Start 2014-02-03 (actual); primary completion 2015-05-08 (actual). Results posted on 2018-01-23.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes
- Acronym
- SUSTAIN™1
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- semaglutide
- Intervention (Drug)
- placebo
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct02054897- Content hash
1730a07161f78a6d636423dd058a0df36e9d51613cfdfd9ca4c67548a131ddd6